| ■ 영문 제목 : Global HDAC Inhibitors Market 2023-2027 | |
![]() | ■ 상품코드 : IRTNTR72719-23 ■ 조사/발행회사 : Technavio ■ 발행일 : 2023년 1월 최신판(2025년 또는 2026년)은 문의주세요. ■ 페이지수 : 약120 ■ 작성언어 : 영문 ■ 보고서 형태 : PDF ■ 납품 방식 : E메일 (24시간 이내) ■ 조사대상 지역 : 북미, 유럽, 아시아 태평양, 기타 지역 ■ 산업 분야 : 의료 |
| Single User (1명 열람용) | USD2,500 ⇒환산₩3,500,000 | 견적의뢰/주문/질문 |
| Enterprise License (동일기업내 공유가능) | USD4,000 ⇒환산₩5,600,000 | 견적의뢰/주문/질문 |
|
※가격옵션 설명 - 납기는 즉일~2일소요됩니다. 3일이상 소요되는 경우는 별도표기 또는 연락드립니다. - 지불방법은 계좌이체/무통장입금 또는 카드결제입니다. |
| Technavio사는 세계의 HDAC 저해제 시장 규모가 2022년에서 2027년 사이에 172.61백만 달러에 달하며, 예측 기간 동안 연평균 7.73% 성장할 것으로 예상하고 있습니다. 본 조사 보고서는 세계의 HDAC 저해제 시장에 대해 조사 및 분석을 실시하여, 개요, 시장 현황, 시장 규모 예측, 과거 시장 규모, Five Force 분석, 투여 경로별 (경구, 비경구) 분석, 유통 채널별 (병원 약국, 소매 약국, 온라인 약국, 기타) 분석, 고객 현황, 지역별 현황 (북미, 유럽, 아시아 태평양, 기타 지역, 미국, 캐나다, 영국, 독일, 중국) 분석, 성장 요인/과제/동향, 기업 현황, 기업 분석 등의 내용을 게재하고 있습니다. 또한 본 조사 보고서는 Actrotech Biopharma Inc., AstraZeneca Plc, Bio Techne Corp., BioVision Inc., Bristol Myers Squibb Co., Celleron Therapeutics Ltd., Curis Inc., Huya Bioscience International LLC, InvivoGen Corp., Italfarmaco Spa, Medivir AB, Merck and Co. Inc., Novartis AG, Onxeo SA, Shenzhen Chipscreen Biotechnology Co. Ltd., Syndax Pharmaceuticals Inc., Tokyo Chemical Industry Co. Ltd., Viracta Therapeutics Inc., Xynomic Pharmaceuticals (Nanjing) Co. Ltd. ., Cetya Therapeutics Inc.와 같은 기업 정보를 포함하고 있습니다. ・개요 ・시장 현황 ・시장 규모 예측 ・과거 시장 규모 ・Five Force 분석 ・세계의 HDAC 저해제 시장 규모 : 투여 경로별 - 경구 투여 HDAC 저해제의 시장 규모 - 비경구 투여 HDAC 저해제의 시장 규모 ・세계의 HDAC 저해제 시장 규모 : 유통 채널별 - 병원 약국 채널의 시장 규모 - 소매 약국 채널의 시장 규모 - 온라인 약국 채널의 시장 규모 - 기타 채널의 시장 규모 ・지역별 현황 - 북미의 HDAC 저해제 시장 규모 - 유럽의 HDAC 저해제 시장 규모 - 아시아 태평양의 HDAC 저해제 시장 규모 - 기타 지역의 HDAC 저해제 시장 규모 - 미국의 HDAC 저해제 시장 규모 - 캐나다의 HDAC 저해제 시장 규모 - 영국의 HDAC 저해제 시장 규모 - 독일의 HDAC 저해제 시장 규모 - 중국의 HDAC 저해제 시장 규모 ・성장 요인/과제/동향 ・기업 현황 ・기업 분석 Technavio 사는 이익, 가격, 경쟁, 프로모션과 같은 주요 매개 변수를 분석하여, 다수의 소스로부터 데이터를 조사, 통합 및 합산하여 HDAC 저해제 시장에 대한 상세하고 종합적인 결과를 제공합니다. 또한, 주요 산업의 영향 요인을 분석하여 시장의 다양한 관점을 제시합니다. 제시된 데이터는 포괄적이고 신뢰할 수 있으며, 1차 및 2차에 걸친 광범위한 조사 결과입니다. 덧붙여 Technavio 사의 시장 조사 보고서는 정확한 HDAC 저해제 시장 성장을 예측하기 위해, 정성적 및 정량적 조사를 사용하여, 명확한 경쟁 현황과 상세한 벤더 선택 방법 및 분석을 제공합니다. |
Technavio는 HDAC(히스톤 탈아세틸화 효소) 억제제 시장을 모니터링하고 있으며, 2022-2027년 동안 1억 7261만 달러 성장할 것으로 예측하고 있습니다. 이 시장은 2022-2027년 동안 연평균 성장률(CAGR) 7.73%로 성장할 것으로 보입니다. HDAC 억제제 시장에 대한 보고서는 시장 규모와 예측, 트렌드, 성장 동력 및 도전 과제, 그리고 약 25개 공급업체를 포함한 벤더 분석을 제공합니다.
현재 시장 상황, 최신 트렌드 및 동향, 전반적인 시장 환경에 대한 분석이 포함되어 있으며, 고도의 타겟 친화성 및 특이성, 높은 암 유병률, 신약 전달 시스템 및 병용 요법 개발 등이 시장 성장을 이끄는 주요 요인으로 작용하고 있습니다.
HDAC 억제제 시장은 다음과 같이 분류됩니다: 경로에 따른 분류(경구 HDAC 억제제, 주사 HDAC 억제제), 유통 경로(병원 약국, 소매 약국, 온라인 약국, 기타), 지리적 분류(북미, 유럽, 아시아, 기타 지역(ROW)).
노인 인구 증가가 HDAC 억제제 시장 성장의 주요 원인으로 지목되고 있으며, 연구 보조금 및 자금 지원, 암에 대한 인식 증대도 시장 수요를 크게 증가시킬 것으로 예상됩니다.
이 보고서는 HDAC 억제제 시장의 크기, 예측 및 산업 분석을 포함하고 있으며, 고객이 시장 위치를 개선할 수 있도록 돕기 위한 강력한 벤더 분석이 포함되어 있습니다. 주요 벤더로는 Acrotech Biopharma Inc., AstraZeneca Plc, Bio Techne Corp., BioVision Inc., Bristol Myers Squibb Co., Celleron Therapeutics Ltd., Curis Inc., Huya Bioscience International LLC, InvivoGen Corp., Italfarmaco Spa, Medivir AB, Merck and Co. Inc., Novartis AG, Onxeo SA, Shenzhen Chipscreen Biotechnology Co. Ltd., Syndax Pharmaceuticals Inc., Tokyo Chemical Industry Co. Ltd., Viracta Therapeutics Inc., Xynomic Pharmaceuticals (Nanjing) Co. Ltd., Cetya Therapeutics Inc. 등이 있습니다. 또한, HDAC 억제제 시장 분석 보고서는 향후 성장 기회에 영향을 미칠 새로운 트렌드와 도전에 대한 정보를 포함하고 있습니다.
이 연구는 산업의 주요 참여자들로부터의 정보와 함께 1차 및 2차 정보를 객관적으로 조합하여 수행되었습니다. 보고서에는 포괄적인 시장 및 벤더 환경과 주요 벤더 분석이 포함되어 있습니다. Technavio는 이 시장에 대한 포괄적이고 신뢰할 수 있는 데이터를 제공하며, 정성적 및 정량적 연구를 통해 정확한 시장 성장을 예측하는 벤더 선정 방법론을 제공합니다.
■ 보고서 목차• 1 요약 • 3 시장 규모 • 4 과거 시장 규모 o 표 19: 투여 경로별 시장 규모 추이 2017-2021년 (백만 달러) o 표 20: 유통 채널별 시장 규모 추이 2017-2021년 (백만 달러) o 표 21: 지역별 시장 규모 추이 2017-2021년 (백만 달러) o 표 22: 국가별 시장 규모 추이 2017-2021년 (백만 달러) 백만) o 표 55: 온라인 약국 차트 – 2022-2027년 시장 규모 및 전망(백만 달러) • 8 고객 현황 • 9 지역별 시장 현황 o 표 101: 중국 시장 규모 및 전망 차트 2022-2027년 (백만 달러) • 10. 주요 동인, 과제 및 트렌드 o 표 158: 자이노믹 파마슈티컬스(난징)(Xynomic Pharmaceuticals (Nanjing) Co. Ltd.) – 제품/서비스 o 표 159: 자이노믹 파마슈티컬스(난징)(Xynomic Pharmaceuticals (Nanjing) Co. Ltd.) – 주요 제공 서비스 첨부 자료: 표 1: 요약 – 시장 개요 차트 첨부자료 66: 2022-2027년 지역별 시장 점유율 데이터표(%) 첨부자료 68: 지역별 비교 데이터표 첨부자료 69: 북미 시장 규모 및 전망 차트(2022-2027년, 백만 달러) 첨부자료 71: 북미 시장 전년 대비 성장률 차트(2022-2027년) 2022-2027년 (%) 첨부자료 127: Curis Inc. – 주요 제품 및 서비스 첨부자료 151: 선전칩스크린 바이오테크놀로지 Co. Ltd. – 주요 제공 서비스 첨부자료 159: Xynomic Pharmaceuticals (Nanjing) Co. Ltd. – 주요 제공 서비스 o 1.1 Market overview o Exhibit 01: Executive Summary - Chart on Market Overview o Exhibit 02: Executive Summary - Data Table on Market Overview o Exhibit 03: Executive Summary - Chart on Global Market Characteristics o Exhibit 04: Executive Summary - Chart on Market by Geography o Exhibit 05: Executive Summary - Chart on Market Segmentation by Route of Administration o Exhibit 06: Executive Summary - Chart on Market Segmentation by Distribution Channel o Exhibit 07: Executive Summary - Chart on Incremental Growth o Exhibit 08: Executive Summary - Data Table on Incremental Growth o Exhibit 09: Executive Summary - Chart on Vendor Market Positioning • 2 Market Landscape o 2.1 Market ecosystem o Exhibit 10: Parent market o Exhibit 11: Market Characteristics • 3 Market Sizing o 3.1 Market definition o Exhibit 12: Offerings of vendors included in the market definition o 3.2 Market segment analysis o Exhibit 13: Market segments o 3.3 Market size 2022 o 3.4 Market outlook: Forecast for 2022-2027 o Exhibit 14: Chart on Global - Market size and forecast 2022-2027 ($ million) o Exhibit 15: Data Table on Global - Market size and forecast 2022-2027 ($ million) o Exhibit 16: Chart on Global Market: Year-over-year growth 2022-2027 (%) o Exhibit 17: Data Table on Global Market: Year-over-year growth 2022-2027 (%) • 4 Historic Market Size o 4.1 Global HDAC (histone deacetylase) inhibitors market 2017 - 2021 o Exhibit 18: Historic Market Size - Data Table on Global HDAC (histone deacetylase) inhibitors market 2017 - 2021 ($ million) o 4.2 Route of administration Segment Analysis 2017 - 2021 o Exhibit 19: Historic Market Size - Route of administration Segment 2017 - 2021 ($ million) o 4.3 Distribution Channel Segment Analysis 2017 - 2021 o Exhibit 20: Historic Market Size - Distribution Channel Segment 2017 - 2021 ($ million) o 4.4 Geography Segment Analysis 2017 - 2021 o Exhibit 21: Historic Market Size - Geography Segment 2017 - 2021 ($ million) o 4.5 Country Segment Analysis 2017 - 2021 o Exhibit 22: Historic Market Size - Country Segment 2017 - 2021 ($ million) • 5 Five Forces Analysis o 5.1 Five forces summary o Exhibit 23: Five forces analysis - Comparison between 2022 and 2027 o 5.2 Bargaining power of buyers o Exhibit 24: Chart on Bargaining power of buyers - Impact of key factors 2022 and 2027 o 5.3 Bargaining power of suppliers o Exhibit 25: Bargaining power of suppliers - Impact of key factors in 2022 and 2027 o 5.4 Threat of new entrants o Exhibit 26: Threat of new entrants - Impact of key factors in 2022 and 2027 o 5.5 Threat of substitutes o Exhibit 27: Threat of substitutes - Impact of key factors in 2022 and 2027 o 5.6 Threat of rivalry o Exhibit 28: Threat of rivalry - Impact of key factors in 2022 and 2027 o 5.7 Market condition o Exhibit 29: Chart on Market condition - Five forces 2022 and 2027 • 6 Market Segmentation by Route of Administration o 6.1 Market segments o Exhibit 30: Chart on Route of Administration - Market share 2022-2027 (%) o Exhibit 31: Data Table on Route of Administration - Market share 2022-2027 (%) o 6.2 Comparison by Route of Administration o Exhibit 32: Chart on Comparison by Route of Administration o Exhibit 33: Data Table on Comparison by Route of Administration o 6.3 Oral HDAC inhibitors - Market size and forecast 2022-2027 o Exhibit 34: Chart on Oral HDAC inhibitors - Market size and forecast 2022-2027 ($ million) o Exhibit 35: Data Table on Oral HDAC inhibitors - Market size and forecast 2022-2027 ($ million) o Exhibit 36: Chart on Oral HDAC inhibitors - Year-over-year growth 2022-2027 (%) o Exhibit 37: Data Table on Oral HDAC inhibitors - Year-over-year growth 2022-2027 (%) o 6.4 Parenteral HDAC inhibitors - Market size and forecast 2022-2027 o Exhibit 38: Chart on Parenteral HDAC inhibitors - Market size and forecast 2022-2027 ($ million) o Exhibit 39: Data Table on Parenteral HDAC inhibitors - Market size and forecast 2022-2027 ($ million) o Exhibit 40: Chart on Parenteral HDAC inhibitors - Year-over-year growth 2022-2027 (%) o Exhibit 41: Data Table on Parenteral HDAC inhibitors - Year-over-year growth 2022-2027 (%) o 6.5 Market opportunity by Route of Administration o Exhibit 42: Market opportunity by Route of Administration ($ million) • 7 Market Segmentation by Distribution Channel o 7.1 Market segments o Exhibit 43: Chart on Distribution Channel - Market share 2022-2027 (%) o Exhibit 44: Data Table on Distribution Channel - Market share 2022-2027 (%) o 7.2 Comparison by Distribution Channel o Exhibit 45: Chart on Comparison by Distribution Channel o Exhibit 46: Data Table on Comparison by Distribution Channel o 7.3 Hospital pharmacies - Market size and forecast 2022-2027 o Exhibit 47: Chart on Hospital pharmacies - Market size and forecast 2022-2027 ($ million) o Exhibit 48: Data Table on Hospital pharmacies - Market size and forecast 2022-2027 ($ million) o Exhibit 49: Chart on Hospital pharmacies - Year-over-year growth 2022-2027 (%) o Exhibit 50: Data Table on Hospital pharmacies - Year-over-year growth 2022-2027 (%) o 7.4 Retail pharmacies - Market size and forecast 2022-2027 o Exhibit 51: Chart on Retail pharmacies - Market size and forecast 2022-2027 ($ million) o Exhibit 52: Data Table on Retail pharmacies - Market size and forecast 2022-2027 ($ million) o Exhibit 53: Chart on Retail pharmacies - Year-over-year growth 2022-2027 (%) o Exhibit 54: Data Table on Retail pharmacies - Year-over-year growth 2022-2027 (%) o 7.5 Online pharmacies - Market size and forecast 2022-2027 o Exhibit 55: Chart on Online pharmacies - Market size and forecast 2022-2027 ($ million) o Exhibit 56: Data Table on Online pharmacies - Market size and forecast 2022-2027 ($ million) o Exhibit 57: Chart on Online pharmacies - Year-over-year growth 2022-2027 (%) o Exhibit 58: Data Table on Online pharmacies - Year-over-year growth 2022-2027 (%) o 7.6 Others - Market size and forecast 2022-2027 o Exhibit 59: Chart on Others - Market size and forecast 2022-2027 ($ million) o Exhibit 60: Data Table on Others - Market size and forecast 2022-2027 ($ million) o Exhibit 61: Chart on Others - Year-over-year growth 2022-2027 (%) o Exhibit 62: Data Table on Others - Year-over-year growth 2022-2027 (%) o 7.7 Market opportunity by Distribution Channel o Exhibit 63: Market opportunity by Distribution Channel ($ million) • 8 Customer Landscape o 8.1 Customer landscape overview o Exhibit 64: Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria • 9 Geographic Landscape o 9.1 Geographic segmentation o Exhibit 65: Chart on Market share by geography 2022-2027 (%) o Exhibit 66: Data Table on Market share by geography 2022-2027 (%) o 9.2 Geographic comparison o Exhibit 67: Chart on Geographic comparison o Exhibit 68: Data Table on Geographic comparison o 9.3 North America - Market size and forecast 2022-2027 o Exhibit 69: Chart on North America - Market size and forecast 2022-2027 ($ million) o Exhibit 70: Data Table on North America - Market size and forecast 2022-2027 ($ million) o Exhibit 71: Chart on North America - Year-over-year growth 2022-2027 (%) o Exhibit 72: Data Table on North America - Year-over-year growth 2022-2027 (%) o 9.4 Europe - Market size and forecast 2022-2027 o Exhibit 73: Chart on Europe - Market size and forecast 2022-2027 ($ million) o Exhibit 74: Data Table on Europe - Market size and forecast 2022-2027 ($ million) o Exhibit 75: Chart on Europe - Year-over-year growth 2022-2027 (%) o Exhibit 76: Data Table on Europe - Year-over-year growth 2022-2027 (%) o 9.5 Asia - Market size and forecast 2022-2027 o Exhibit 77: Chart on Asia - Market size and forecast 2022-2027 ($ million) o Exhibit 78: Data Table on Asia - Market size and forecast 2022-2027 ($ million) o Exhibit 79: Chart on Asia - Year-over-year growth 2022-2027 (%) o Exhibit 80: Data Table on Asia - Year-over-year growth 2022-2027 (%) o 9.6 Rest of World (ROW) - Market size and forecast 2022-2027 o Exhibit 81: Chart on Rest of World (ROW) - Market size and forecast 2022-2027 ($ million) o Exhibit 82: Data Table on Rest of World (ROW) - Market size and forecast 2022-2027 ($ million) o Exhibit 83: Chart on Rest of World (ROW) - Year-over-year growth 2022-2027 (%) o Exhibit 84: Data Table on Rest of World (ROW) - Year-over-year growth 2022-2027 (%) o 9.7 US - Market size and forecast 2022-2027 o Exhibit 85: Chart on US - Market size and forecast 2022-2027 ($ million) o Exhibit 86: Data Table on US - Market size and forecast 2022-2027 ($ million) o Exhibit 87: Chart on US - Year-over-year growth 2022-2027 (%) o Exhibit 88: Data Table on US - Year-over-year growth 2022-2027 (%) o 9.8 Canada - Market size and forecast 2022-2027 o Exhibit 89: Chart on Canada - Market size and forecast 2022-2027 ($ million) o Exhibit 90: Data Table on Canada - Market size and forecast 2022-2027 ($ million) o Exhibit 91: Chart on Canada - Year-over-year growth 2022-2027 (%) o Exhibit 92: Data Table on Canada - Year-over-year growth 2022-2027 (%) o 9.9 UK - Market size and forecast 2022-2027 o Exhibit 93: Chart on UK - Market size and forecast 2022-2027 ($ million) o Exhibit 94: Data Table on UK - Market size and forecast 2022-2027 ($ million) o Exhibit 95: Chart on UK - Year-over-year growth 2022-2027 (%) o Exhibit 96: Data Table on UK - Year-over-year growth 2022-2027 (%) o 9.10 Germany - Market size and forecast 2022-2027 o Exhibit 97: Chart on Germany - Market size and forecast 2022-2027 ($ million) o Exhibit 98: Data Table on Germany - Market size and forecast 2022-2027 ($ million) o Exhibit 99: Chart on Germany - Year-over-year growth 2022-2027 (%) o Exhibit 100: Data Table on Germany - Year-over-year growth 2022-2027 (%) o 9.11 China - Market size and forecast 2022-2027 o Exhibit 101: Chart on China - Market size and forecast 2022-2027 ($ million) o Exhibit 102: Data Table on China - Market size and forecast 2022-2027 ($ million) o Exhibit 103: Chart on China - Year-over-year growth 2022-2027 (%) o Exhibit 104: Data Table on China - Year-over-year growth 2022-2027 (%) o 9.12 Market opportunity by geography o Exhibit 105: Market opportunity by geography ($ million) • 10 Drivers, Challenges, and Trends o 10.1 Market drivers o 10.2 Market challenges o 10.3 Impact of drivers and challenges o Exhibit 106: Impact of drivers and challenges in 2022 and 2027 o 10.4 Market trends • 11 Vendor Landscape o 11.1 Overview o 11.2 Vendor landscape o Exhibit 107: Overview on Criticality of inputs and Factors of differentiation o 11.3 Landscape disruption o Exhibit 108: Overview on factors of disruption o 11.4 Industry risks o Exhibit 109: Impact of key risks on business • 12 Vendor Analysis o 12.1 Vendors covered o Exhibit 110: Vendors covered o 12.2 Market positioning of vendors o Exhibit 111: Matrix on vendor position and classification o 12.3 Acrotech Biopharma Inc. o Exhibit 112: Acrotech Biopharma Inc. - Overview o Exhibit 113: Acrotech Biopharma Inc. - Product / Service o Exhibit 114: Acrotech Biopharma Inc. - Key offerings o 12.4 AstraZeneca Plc o Exhibit 115: AstraZeneca Plc - Overview o Exhibit 116: AstraZeneca Plc - Product / Service o Exhibit 117: AstraZeneca Plc - Key news o Exhibit 118: AstraZeneca Plc - Key offerings o 12.5 Bristol Myers Squibb Co. o Exhibit 119: Bristol Myers Squibb Co. - Overview o Exhibit 120: Bristol Myers Squibb Co. - Product / Service o Exhibit 121: Bristol Myers Squibb Co. - Key news o Exhibit 122: Bristol Myers Squibb Co. - Key offerings o 12.6 Celleron Therapeutics Ltd. o Exhibit 123: Celleron Therapeutics Ltd. - Overview o Exhibit 124: Celleron Therapeutics Ltd. - Key offerings o 12.7 Curis Inc. o Exhibit 125: Curis Inc. - Overview o Exhibit 126: Curis Inc. - Product / Service o Exhibit 127: Curis Inc. - Key offerings o 12.8 Huya Bioscience International LLC o Exhibit 128: Huya Bioscience International LLC - Overview o Exhibit 129: Huya Bioscience International LLC - Product / Service o Exhibit 130: Huya Bioscience International LLC - Key offerings o 12.9 Italfarmaco Spa o Exhibit 131: Italfarmaco Spa - Overview o Exhibit 132: Italfarmaco Spa - Product / Service o Exhibit 133: Italfarmaco Spa - Key offerings o 12.10 Medivir AB o Exhibit 134: Medivir AB - Overview o Exhibit 135: Medivir AB - Product / Service o Exhibit 136: Medivir AB - Key offerings o 12.11 Merck and Co. Inc. o Exhibit 137: Merck and Co. Inc. - Overview o Exhibit 138: Merck and Co. Inc. - Business segments o Exhibit 139: Merck and Co. Inc. - Key news o Exhibit 140: Merck and Co. Inc. - Key offerings o Exhibit 141: Merck and Co. Inc. - Segment focus o 12.12 Novartis AG o Exhibit 142: Novartis AG - Overview o Exhibit 143: Novartis AG - Business segments o Exhibit 144: Novartis AG - Key offerings o Exhibit 145: Novartis AG - Segment focus o 12.13 Onxeo SA o Exhibit 146: Onxeo SA - Overview o Exhibit 147: Onxeo SA - Product / Service o Exhibit 148: Onxeo SA - Key offerings o 12.14 Shenzhen Chipscreen Biotechnology Co. Ltd. o Exhibit 149: Shenzhen Chipscreen Biotechnology Co. Ltd. - Overview o Exhibit 150: Shenzhen Chipscreen Biotechnology Co. Ltd. - Product / Service o Exhibit 151: Shenzhen Chipscreen Biotechnology Co. Ltd. - Key offerings o 12.15 Syndax Pharmaceuticals Inc. o Exhibit 152: Syndax Pharmaceuticals Inc. - Overview o Exhibit 153: Syndax Pharmaceuticals Inc. - Key offerings o 12.16 Viracta Therapeutics Inc. o Exhibit 154: Viracta Therapeutics Inc. - Overview o Exhibit 155: Viracta Therapeutics Inc. - Product / Service o Exhibit 156: Viracta Therapeutics Inc. - Key offerings o 12.17 Xynomic Pharmaceuticals (Nanjing) Co. Ltd. o Exhibit 157: Xynomic Pharmaceuticals (Nanjing) Co. Ltd. - Overview o Exhibit 158: Xynomic Pharmaceuticals (Nanjing) Co. Ltd. - Product / Service o Exhibit 159: Xynomic Pharmaceuticals (Nanjing) Co. Ltd. - Key offerings • 13 Appendix o 13.1 Scope of the report o 13.2 Inclusions and exclusions checklist o Exhibit 160: Inclusions checklist o Exhibit 161: Exclusions checklist o 13.3 Currency conversion rates for US$ o Exhibit 162: Currency conversion rates for US$ o 13.4 Research methodology o Exhibit 163: Research methodology o Exhibit 164: Validation techniques employed for market sizing o Exhibit 165: Information sources o 13.5 List of abbreviations o Exhibit 166: List of abbreviations Exhibits: Exhibits1: Executive Summary - Chart on Market Overview Exhibits2: Executive Summary - Data Table on Market Overview Exhibits3: Executive Summary - Chart on Global Market Characteristics Exhibits4: Executive Summary - Chart on Market by Geography Exhibits5: Executive Summary - Chart on Market Segmentation by Route of Administration Exhibits6: Executive Summary - Chart on Market Segmentation by Distribution Channel Exhibits7: Executive Summary - Chart on Incremental Growth Exhibits8: Executive Summary - Data Table on Incremental Growth Exhibits9: Executive Summary - Chart on Vendor Market Positioning Exhibits10: Parent market Exhibits11: Market Characteristics Exhibits12: Offerings of vendors included in the market definition Exhibits13: Market segments Exhibits14: Chart on Global - Market size and forecast 2022-2027 ($ million) Exhibits15: Data Table on Global - Market size and forecast 2022-2027 ($ million) Exhibits16: Chart on Global Market: Year-over-year growth 2022-2027 (%) Exhibits17: Data Table on Global Market: Year-over-year growth 2022-2027 (%) Exhibits18: Historic Market Size - Data Table on Global HDAC (histone deacetylase) inhibitors market 2017 - 2021 ($ million) Exhibits19: Historic Market Size - Route of administration Segment 2017 - 2021 ($ million) Exhibits20: Historic Market Size - Distribution Channel Segment 2017 - 2021 ($ million) Exhibits21: Historic Market Size - Geography Segment 2017 - 2021 ($ million) Exhibits22: Historic Market Size - Country Segment 2017 - 2021 ($ million) Exhibits23: Five forces analysis - Comparison between 2022 and 2027 Exhibits24: Chart on Bargaining power of buyers - Impact of key factors 2022 and 2027 Exhibits25: Bargaining power of suppliers - Impact of key factors in 2022 and 2027 Exhibits26: Threat of new entrants - Impact of key factors in 2022 and 2027 Exhibits27: Threat of substitutes - Impact of key factors in 2022 and 2027 Exhibits28: Threat of rivalry - Impact of key factors in 2022 and 2027 Exhibits29: Chart on Market condition - Five forces 2022 and 2027 Exhibits30: Chart on Route of Administration - Market share 2022-2027 (%) Exhibits31: Data Table on Route of Administration - Market share 2022-2027 (%) Exhibits32: Chart on Comparison by Route of Administration Exhibits33: Data Table on Comparison by Route of Administration Exhibits34: Chart on Oral HDAC inhibitors - Market size and forecast 2022-2027 ($ million) Exhibits35: Data Table on Oral HDAC inhibitors - Market size and forecast 2022-2027 ($ million) Exhibits36: Chart on Oral HDAC inhibitors - Year-over-year growth 2022-2027 (%) Exhibits37: Data Table on Oral HDAC inhibitors - Year-over-year growth 2022-2027 (%) Exhibits38: Chart on Parenteral HDAC inhibitors - Market size and forecast 2022-2027 ($ million) Exhibits39: Data Table on Parenteral HDAC inhibitors - Market size and forecast 2022-2027 ($ million) Exhibits40: Chart on Parenteral HDAC inhibitors - Year-over-year growth 2022-2027 (%) Exhibits41: Data Table on Parenteral HDAC inhibitors - Year-over-year growth 2022-2027 (%) Exhibits42: Market opportunity by Route of Administration ($ million) Exhibits43: Chart on Distribution Channel - Market share 2022-2027 (%) Exhibits44: Data Table on Distribution Channel - Market share 2022-2027 (%) Exhibits45: Chart on Comparison by Distribution Channel Exhibits46: Data Table on Comparison by Distribution Channel Exhibits47: Chart on Hospital pharmacies - Market size and forecast 2022-2027 ($ million) Exhibits48: Data Table on Hospital pharmacies - Market size and forecast 2022-2027 ($ million) Exhibits49: Chart on Hospital pharmacies - Year-over-year growth 2022-2027 (%) Exhibits50: Data Table on Hospital pharmacies - Year-over-year growth 2022-2027 (%) Exhibits51: Chart on Retail pharmacies - Market size and forecast 2022-2027 ($ million) Exhibits52: Data Table on Retail pharmacies - Market size and forecast 2022-2027 ($ million) Exhibits53: Chart on Retail pharmacies - Year-over-year growth 2022-2027 (%) Exhibits54: Data Table on Retail pharmacies - Year-over-year growth 2022-2027 (%) Exhibits55: Chart on Online pharmacies - Market size and forecast 2022-2027 ($ million) Exhibits56: Data Table on Online pharmacies - Market size and forecast 2022-2027 ($ million) Exhibits57: Chart on Online pharmacies - Year-over-year growth 2022-2027 (%) Exhibits58: Data Table on Online pharmacies - Year-over-year growth 2022-2027 (%) Exhibits59: Chart on Others - Market size and forecast 2022-2027 ($ million) Exhibits60: Data Table on Others - Market size and forecast 2022-2027 ($ million) Exhibits61: Chart on Others - Year-over-year growth 2022-2027 (%) Exhibits62: Data Table on Others - Year-over-year growth 2022-2027 (%) Exhibits63: Market opportunity by Distribution Channel ($ million) Exhibits64: Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria Exhibits65: Chart on Market share by geography 2022-2027 (%) Exhibits66: Data Table on Market share by geography 2022-2027 (%) Exhibits67: Chart on Geographic comparison Exhibits68: Data Table on Geographic comparison Exhibits69: Chart on North America - Market size and forecast 2022-2027 ($ million) Exhibits70: Data Table on North America - Market size and forecast 2022-2027 ($ million) Exhibits71: Chart on North America - Year-over-year growth 2022-2027 (%) Exhibits72: Data Table on North America - Year-over-year growth 2022-2027 (%) Exhibits73: Chart on Europe - Market size and forecast 2022-2027 ($ million) Exhibits74: Data Table on Europe - Market size and forecast 2022-2027 ($ million) Exhibits75: Chart on Europe - Year-over-year growth 2022-2027 (%) Exhibits76: Data Table on Europe - Year-over-year growth 2022-2027 (%) Exhibits77: Chart on Asia - Market size and forecast 2022-2027 ($ million) Exhibits78: Data Table on Asia - Market size and forecast 2022-2027 ($ million) Exhibits79: Chart on Asia - Year-over-year growth 2022-2027 (%) Exhibits80: Data Table on Asia - Year-over-year growth 2022-2027 (%) Exhibits81: Chart on Rest of World (ROW) - Market size and forecast 2022-2027 ($ million) Exhibits82: Data Table on Rest of World (ROW) - Market size and forecast 2022-2027 ($ million) Exhibits83: Chart on Rest of World (ROW) - Year-over-year growth 2022-2027 (%) Exhibits84: Data Table on Rest of World (ROW) - Year-over-year growth 2022-2027 (%) Exhibits85: Chart on US - Market size and forecast 2022-2027 ($ million) Exhibits86: Data Table on US - Market size and forecast 2022-2027 ($ million) Exhibits87: Chart on US - Year-over-year growth 2022-2027 (%) Exhibits88: Data Table on US - Year-over-year growth 2022-2027 (%) Exhibits89: Chart on Canada - Market size and forecast 2022-2027 ($ million) Exhibits90: Data Table on Canada - Market size and forecast 2022-2027 ($ million) Exhibits91: Chart on Canada - Year-over-year growth 2022-2027 (%) Exhibits92: Data Table on Canada - Year-over-year growth 2022-2027 (%) Exhibits93: Chart on UK - Market size and forecast 2022-2027 ($ million) Exhibits94: Data Table on UK - Market size and forecast 2022-2027 ($ million) Exhibits95: Chart on UK - Year-over-year growth 2022-2027 (%) Exhibits96: Data Table on UK - Year-over-year growth 2022-2027 (%) Exhibits97: Chart on Germany - Market size and forecast 2022-2027 ($ million) Exhibits98: Data Table on Germany - Market size and forecast 2022-2027 ($ million) Exhibits99: Chart on Germany - Year-over-year growth 2022-2027 (%) Exhibits100: Data Table on Germany - Year-over-year growth 2022-2027 (%) Exhibits101: Chart on China - Market size and forecast 2022-2027 ($ million) Exhibits102: Data Table on China - Market size and forecast 2022-2027 ($ million) Exhibits103: Chart on China - Year-over-year growth 2022-2027 (%) Exhibits104: Data Table on China - Year-over-year growth 2022-2027 (%) Exhibits105: Market opportunity by geography ($ million) Exhibits106: Impact of drivers and challenges in 2022 and 2027 Exhibits107: Overview on Criticality of inputs and Factors of differentiation Exhibits108: Overview on factors of disruption Exhibits109: Impact of key risks on business Exhibits110: Vendors covered Exhibits111: Matrix on vendor position and classification Exhibits112: Acrotech Biopharma Inc. - Overview Exhibits113: Acrotech Biopharma Inc. - Product / Service Exhibits114: Acrotech Biopharma Inc. - Key offerings Exhibits115: AstraZeneca Plc - Overview Exhibits116: AstraZeneca Plc - Product / Service Exhibits117: AstraZeneca Plc - Key news Exhibits118: AstraZeneca Plc - Key offerings Exhibits119: Bristol Myers Squibb Co. - Overview Exhibits120: Bristol Myers Squibb Co. - Product / Service Exhibits121: Bristol Myers Squibb Co. - Key news Exhibits122: Bristol Myers Squibb Co. - Key offerings Exhibits123: Celleron Therapeutics Ltd. - Overview Exhibits124: Celleron Therapeutics Ltd. - Key offerings Exhibits125: Curis Inc. - Overview Exhibits126: Curis Inc. - Product / Service Exhibits127: Curis Inc. - Key offerings Exhibits128: Huya Bioscience International LLC - Overview Exhibits129: Huya Bioscience International LLC - Product / Service Exhibits130: Huya Bioscience International LLC - Key offerings Exhibits131: Italfarmaco Spa - Overview Exhibits132: Italfarmaco Spa - Product / Service Exhibits133: Italfarmaco Spa - Key offerings Exhibits134: Medivir AB - Overview Exhibits135: Medivir AB - Product / Service Exhibits136: Medivir AB - Key offerings Exhibits137: Merck and Co. Inc. - Overview Exhibits138: Merck and Co. Inc. - Business segments Exhibits139: Merck and Co. Inc. - Key news Exhibits140: Merck and Co. Inc. - Key offerings Exhibits141: Merck and Co. Inc. - Segment focus Exhibits142: Novartis AG - Overview Exhibits143: Novartis AG - Business segments Exhibits144: Novartis AG - Key offerings Exhibits145: Novartis AG - Segment focus Exhibits146: Onxeo SA - Overview Exhibits147: Onxeo SA - Product / Service Exhibits148: Onxeo SA - Key offerings Exhibits149: Shenzhen Chipscreen Biotechnology Co. Ltd. - Overview Exhibits150: Shenzhen Chipscreen Biotechnology Co. Ltd. - Product / Service Exhibits151: Shenzhen Chipscreen Biotechnology Co. Ltd. - Key offerings Exhibits152: Syndax Pharmaceuticals Inc. - Overview Exhibits153: Syndax Pharmaceuticals Inc. - Key offerings Exhibits154: Viracta Therapeutics Inc. - Overview Exhibits155: Viracta Therapeutics Inc. - Product / Service Exhibits156: Viracta Therapeutics Inc. - Key offerings Exhibits157: Xynomic Pharmaceuticals (Nanjing) Co. Ltd. - Overview Exhibits158: Xynomic Pharmaceuticals (Nanjing) Co. Ltd. - Product / Service Exhibits159: Xynomic Pharmaceuticals (Nanjing) Co. Ltd. - Key offerings Exhibits160: Inclusions checklist Exhibits161: Exclusions checklist Exhibits162: Currency conversion rates for US$ Exhibits163: Research methodology Exhibits164: Validation techniques employed for market sizing Exhibits165: Information sources Exhibits166: List of abbreviations |
| ※참고 정보 HDAC 저해제(HDAC Inhibitors)는 히스톤 탈아세틸화 효소(Histone Deacetylases, HDAC)를 억제하는 화합물로, 주로 암 연구와 치료에 중요한 역할을 한다. 히스톤 탈아세틸화 효소는 히스톤 단백질의 아세틸기 제거를 통해 DNA와 히스톤 간의 결합을 강화시켜 유전자 발현을 억제하는 기능을 수행한다. 이 과정은 세포의 성장, 분화 및 주기 조절에 필수적이다. 따라서 HDAC 저해제를 사용하면 히스톤의 아세틸화가 증가하여 유전자 발현이 촉진되고, 이는 다양한 생리적 및 병리적 과정에 영향을 미칠 수 있다. HDAC 저해제는 크게 두 가지 계열로 나뉜다. 첫째는 리간드 결합을 통해 직접적으로 효소의 활성 부위를 억제하는 작은 분자 화합물이며, 둘째는 단백질이나 RNA와 같은 다른 생물학적 분자와의 상호작용을 통해 간접적으로 HDAC의 활성을 억제하는 물질이다. 이러한 HDAC 저해제는 주로 암 치료에 활용되지만, 신경퇴행성 질환, 염증, 대사증후군 등 다양한 질환의 치료 연구에서도 중요한 역할을 하고 있다. 현재까지도 여러 종류의 HDAC 저해제가 개발되어 있으며, 이들은 다양하게 분류될 수 있다. 예를 들어, 1세대 HDAC 저해제로 알려진 발프로산(Valproic Acid)이나 트리코스타틴 A(Trichostatin A)는 피험자 세포에서 유전자 발현 증진이 확인된 바 있다. 2세대 HDAC 저해제로는 발리나(Valproate) 또는 벨리타마이드(Belinostat)와 같은 약물이 있는데, 이들은 이미 임상에서 사용되고 있다. 또한, 3세대 HDAC 저해제는 보다 선택적인 표적을 가지고 있어 특정 HDAC 동종체를 억제하는 방법으로 연구되고 있다. HDAC 저해제는 암 세포의 성장을 저해하고 세포 사멸을 유도하여 종양의 크기를 줄이는 데 기여한다. 특히, 다발성 골수종, 호지킨 림프종, 고형암 등 다양한 암 종류에 대해 긍정적인 임상 결과를 보였다. 이러한 약물들은 단독 요법뿐 아니라 다른 항암제와의 병용 치료에서도 좋은 시너지를 낼 수 있는 것으로 알려져 있다. 더욱이 HDAC 저해제는 비암성 질환에서도 많은 잠재력을 가지고 있다. 예를 들어, 아두카베인(Adalimumab)과 같은 약물은 자가면역 질환에서 발휘되는 항염증 작용을 통해 HDAC 억제효과를 보인다. 또한, 알츠하이머병, 파킨슨병 등의 신경퇴행성 질환에서는 뇌세포의 생존을 촉진하고 인지 기능 향상에 기여할 수 있는 연구가 진행되고 있다. 최근 연구에서는 HDAC 저해제가 유전자의 표현형을 조절하고 환경적 요인에 대한 세포의 반응성을 높이는 것으로 나타났다. 이는 생활 습관 변화나 환경적 요인에 의한 돌발적 유전자 발현 변화에 적응하는 데 도움을 줄 수 있다는 가능성을 의미한다. 이러한 HDAC 저해제의 다각적인 작용을 통해 많은 질병의 치료 방법이 혁신적으로 발전할 수 있을 것으로 기대된다. HDAC 저해제의 발견과 연구는 현재도 활발히 진행 중이며, 보다 안전하고 효과적인 신약 개발이 이루어질 예정이다. 이러한 연구는 강력한 항암 효과 및 다양한 질병 치료에 기여할 수 있는 큰 기회를 제공하고 있다. HDAC 저해제는 단순히 “암 치료”를 넘어, 역동적이고 복잡한 생물학적 체계 속에서 다양한 질병의 메커니즘을 이해하고 이를 기반으로 한 새로운 치료 접근 방안을 제시할 수 있는 중요한 영역으로 자리 잡고 있다. |
| ※본 조사보고서 [세계의 HDAC 저해제 시장 (2023년~2027년)] (코드 : IRTNTR72719-23) 판매에 관한 면책사항을 반드시 확인하세요. |
| ※본 조사보고서 [세계의 HDAC 저해제 시장 (2023년~2027년)] 에 대해서 E메일 문의는 여기를 클릭하세요. |

